MAGNETOM Avanto Fit
Siemens Medical Solutions USA, Inc. • Radiology • 04/01/2022
Device Purpose
The MAGNETOM Avanto Fit is a 1.5T magnetic resonance diagnostic device designed to produce detailed anatomical and functional images, including spectroscopic data, for diagnostic purposes across various body regions and for guiding interventional procedures. It utilizes updated hardware and new syngo MR XA50A software features, such as TSE MoCo for motion correction and AbsoluteShim for improved field homogeneity, to enhance image quality and expand clinical applications.
Summary
The MAGNETOM Avanto Fit is a 1.5 Tesla magnetic resonance diagnostic device (MRDD) designed to assist physicians in diagnosis by producing a variety of images and spectra. It can generate transverse, sagittal, coronal, and oblique cross-sectional images, as well as spectroscopic images and spectra, to display the internal structure and function of the head, body, or extremities. The system allows for the use of contrast agents depending on the area of interest and can also derive other physical parameters from the acquired data. Furthermore, the MAGNETOM Avanto Fit can be utilized for imaging during interventional procedures, provided MR-compatible equipment such as in-room displays and MR Safe biopsy needles are used. This system, running syngo MR XA50A software, represents an upgrade from the MAGNETOM Avanto, incorporating modified hardware and new software functionalities. Hardware updates include a redesigned cover accommodating BioMatrix components and an upgraded Electronic Power Cabinet. Key software enhancements introduce TSE MoCo for image-based motion correction in TSE sequences, automatic fiducial detection to improve MR Breast Biopsy procedures, and AbsoluteShim, a 3-echo gradient echo protocol for shimming. It also features a modified Fast GRE RefScan for optimized reference scanning in echo planar imaging. Non-clinical testing, including image quality assessments with sample clinical images, performance bench tests, and software verification, confirmed that the device performs as intended and its new/modified components maintain an equivalent safety and performance profile.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the "TSE MoCo" image-based motion correction specifically improve image quality in TSE pulse sequences compared to previous motion correction techniques or sequences without it?; What is the quantifiable impact of the "automatic fiducial detection" feature on the efficiency and accuracy of MR Breast Biopsy procedures?; Can the "AbsoluteShim" procedure, based on a 3-echo gradient echo protocol, achieve more homogeneous magnetic fields across diverse patient anatomies or challenging regions compared to standard shimming techniques?; What are the specific performance benefits (e.g., scan time reduction, SNR improvement) of the "Fast GRE RefScan" for GRAPPA and SMS kernel calibration in echo planar imaging?; Beyond the BioMatrix components mentioned for the cover, are there other BioMatrix technologies integrated into the MAGNETOM Avanto Fit, and how do they contribute to image quality or patient experience?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of HBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, ML-BOM, SaaSBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly